BidaskClub upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a report issued on Thursday.
CRSP has been the subject of a number of other research reports. SunTrust Banks reiterated a buy rating on shares of Crispr Therapeutics in a research report on Monday, December 31st. Zacks Investment Research upgraded Crispr Therapeutics from a hold rating to a buy rating and set a $33.00 price objective for the company in a research report on Thursday, January 3rd. Wells Fargo & Co began coverage on Crispr Therapeutics in a research report on Wednesday, October 10th. They set an outperform rating and a $65.00 price objective for the company. Raymond James began coverage on Crispr Therapeutics in a research report on Thursday, September 20th. They set an underperform rating for the company. Finally, Needham & Company LLC began coverage on Crispr Therapeutics in a research report on Sunday, December 9th. They set a buy rating and a $38.72 price objective for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $59.19.
Shares of NASDAQ CRSP opened at $35.15 on Thursday. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -20.56 and a beta of 3.48. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $73.90.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.33). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $2.64 million. Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The business’s revenue for the quarter was down 76.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.62) earnings per share. On average, equities research analysts predict that Crispr Therapeutics will post -3.26 earnings per share for the current year.
In other Crispr Therapeutics news, major shareholder Vertex Pharmaceuticals (Europe bought 90,742 shares of Crispr Therapeutics stock in a transaction dated Monday, December 24th. The stock was bought at an average price of $24.08 per share, for a total transaction of $2,185,067.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 17,310 shares of the stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the sale, the president now owns 1,130,697 shares of the company’s stock, valued at approximately $39,676,157.73. The disclosure for this sale can be found here. Insiders bought 153,682 shares of company stock valued at $3,700,718 in the last 90 days. Corporate insiders own 37.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in shares of Crispr Therapeutics by 211.2% in the third quarter. ARK Investment Management LLC now owns 1,453,590 shares of the company’s stock worth $64,467,000 after acquiring an additional 986,450 shares during the last quarter. Jennison Associates LLC acquired a new position in shares of Crispr Therapeutics in the third quarter worth $23,988,000. EcoR1 Capital LLC acquired a new position in shares of Crispr Therapeutics in the third quarter worth $22,175,000. Orbimed Advisors LLC increased its stake in shares of Crispr Therapeutics by 375.3% in the second quarter. Orbimed Advisors LLC now owns 496,200 shares of the company’s stock worth $29,157,000 after acquiring an additional 391,799 shares during the last quarter. Finally, Valiant Capital Management L.P. acquired a new position in shares of Crispr Therapeutics in the third quarter worth $12,050,000. Institutional investors own 43.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Story: Ex-Dividend
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.